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Abstract
Traditionally, infection with Plasmodium vivax was thought to be benign and self-limiting, however, recent
evidence has demonstrated that infection with P. vivax can also result in severe illness and death. Research into P.
vivax has been relatively neglected and much remains unknown regarding the biology, pathogenesis and
epidemiology of this parasite. One of the fundamental factors governing transmission and immunity is parasite
diversity. An understanding of parasite population genetic structure is necessary to understand the epidemiology,
diversity, distribution and dynamics of natural P. vivax populations. In addition, studying the population structure of
genes under immune selection also enables investigation of the dynamic interplay between transmission and
immunity, which is crucial for vaccine development. A lack of knowledge regarding the transmission and spread of
P. vivax has been particularly highlighted in areas where malaria control and elimination programmes have made
progress in reducing the burden of Plasmodium falciparum, yet P. vivax remains as a substantial obstacle. With
malaria elimination back on the global agenda, mapping of global and local P. vivax population structure is
essential prior to establishing goals for elimination and the roll-out of interventions. A detailed knowledge of the
spatial distribution, transmission and clinical burden of P. vivax is required to act as a benchmark against which
control targets can be set and measured. This paper presents an overview of what is known and what is yet to be
fully understood regarding P. vivax population genetics, as well as the importance and application of P. vivax
population genetics studies.
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Plasmodium vivax: a global health threat
Presently, 2.85 billion people globally are at risk of Plas-
modium vivax malaria infection [1]. Worldwide the
regional incidence of P. vivax has been increasing despite
a decrease in Plasmodium falciparum cases [2-5]. The
most geographically widespread of the six Plasmodium
species that infect humans, P. vivax is a major health
threat to huge populations throughout Asia, the Middle
East and the Pacific [1], where approximately 80 to 90%
of the global P. vivax burden is concentrated [6]. A sig-
nificant number of P. vivax cases also occur throughout
Central and South America, and East and South Africa
[6]. Despite this, research into P. vivax malaria has been
relatively neglected and much detail of the biology,
pathogenesis and epidemiology of this parasite remains
unknown. Traditionally, infection with P. vivax was
thought to be benign and self-limiting and was not con-
sidered a research priority in comparison with the enor-
mous burden of morbidity and mortality presented by P.
falciparum [7,8]. Recent evidence is however challenging
the long-held notion of the benign nature of P. vivax
malaria, demonstrating that infection with P. vivax can
also result in severe illness and death [9-14]. Indeed, the
severe manifestations of P. vivax disease are very similar
to those caused by P. falciparum and include cerebral
malaria, acute respiratory distress, lung injury, renal fail-
ure, hepatic dysfunction, shock and death [12,14].
Lack of knowledge regarding the transmission and
spread of P. vivax has been particularly highlighted in
areas where malaria control and elimination pro-
grammes have made progress in reducing the burden of
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obstacle [15]. The emergence and spread of drug resis-
tant P. vivax is also of serious concern. Indeed, in the
context of achieving malaria elimination targets, reports
of primaquine resistance, the only available treatment to
prevent relapse, is particularly worrisome [16,17]. One
of the key problems undermining effective malaria con-
trol is a lack of understanding of the underlying P. vivax
population structure and transmission dynamics. Popu-
lation genetic studies are needed to define the diversity,
distribution and dynamics of P. vivax populations, as
parasite populations differ widely between locations, due
to factors including prevalence, vector species, host
genetics and a variety of environmental influences
[18-21]. Mapping of global and local P. vivax population
structure is essential prior to establishing goals for elim-
ination and the rollout of interventions, and detailed
knowledge of the spatial distribution, transmission and
clinical burden of P. vivax is required to act as a bench-
mark against which control targets can be set and mea-
sured [1,19,22,23]. The Malaria Eradication Research
Agenda (malERA) Consultative Group on Basic Science
and Enabling Technologies recently reported that no
campaign for malaria control or elimination can proceed
without a comprehensive knowledge of disease epide-
miology and host-parasite-vector interactions, and how
these interactions are affected by intensified intervention
measures [24].
Genetic diversity of Plasmodium vivax
Within a malaria endemic area, multiple parasite clones
can often co-infect the same host. To understand local
population structure and genetic diversity, it is essential
to be able to distinguish between distinct clones within
the same infection as well as between infections. Not
only useful in the context of molecular epidemiology
studies, identifying and managing multiple clone infec-
tions may have additional public health implications, as
increasing, or high levels of multiple clone P. vivax
infections may drive increases in parasite virulence and
fitness, as parasite clones compete for both resources
within the infected host and survival against antimalarial
interventions [25]. However, identifying, and distinguish-
ing between clones can be difficult because the genetic
diversity of P. vivax populations can vary significantly
due to variations in malaria epidemiology in different
r e g i o n s[ 2 6 , 2 7 ] .I s o l a t e so b t a i n e df r o md i s t i n c tp o p u l a -
tions can either be genetically very diverse, so that mul-
tiple infections are easy to determine using a single
molecular marker, or they can have quite low levels of
diversity or even be clonal in the case of very low trans-
mission or epidemics, which makes it more difficult to
distinguish polyclonal from true monoclonal infections
[28].
Genotyping to determine the multiplicity of infection
(MOI) can be performed using either one or two mar-
kers that are extremely polymorphic, or a larger number
of less polymorphic genome-wide markers. Currently,
regions of the genome containing polymorphic repeat
sequences, such as microsatellites or surface antigen
genes, are the markers of choice for doing this. Microsa-
tellite markers are short, tandem, one to six nucleotide
repeats, found frequently throughout the genome and
are typically, selectively neutral. Prior to the identifica-
tion of microsatellites, earlier studies genotyped strains
on the basis of polymorphic coding regions within para-
site antigens such as the circumsporozoite protein (CSP)
and the merozoite surface protein 3 alpha (MSP-3a), for
which there are fewer alleles than the microsatellite
markers [25,29]. Therefore, the number of clones per
infection was most likely underestimated (Table 1).
The population genetic structure of P. falciparum is
closely associated with transmission intensity, hence
population structure and diversity varies greatly accord-
ing to geographical location, at least on a global scale
[65,66]. Plasmodium falciparum populations in regions
with low levels of transmission generally have low pro-
portions of polyclonal infection high levels of linkage
disequilibrium (LD) suggesting significant inbreeding
a n di n f r e q u e n tr e c o m b i n a t i on. The inverse is also true,
with parasite populations in high transmission areas
characterized by a high proportion of multiple infections
low levels of LD suggesting significant outcrossing and
frequent recombination [27,65]. Few studies have been
performed amongst sympatric populations of P. vivax
and P. falciparum, however from what is known, there
appears to be a distinctly different model of population
structure for P. vivax compared to that of P. falciparum
[2,25,27,37]. Using samples collected from a low trans-
mission setting in rural Amazonia, Ferreira and collea-
gues reported higher genetic diversity and frequency of
polyclonal infections for P. vivax compared to P. falci-
parum [2]. Interestingly, strong LD, and frequent repla-
cement of predominant microsatellite haplotypes over
time was also observed amongst the same P. vivax
population [2]. The unique biology of P. vivax is likely
to be responsible for the apparent paradox of multiple
clone infection in a low transmission setting. The latent
hypnozoite stage of the P. vivax lifecycle increases the
likelihood of superinfection with a second clone, poten-
tially resulting in the reactivation of heterologous hyp-
nozoites and an increased likelihood of meiotic
recombination, ultimately increasing genetic diversity
within the population [2,33].
Indeed, microsatellite genotyping has revealed that the
level of genetic variability is highly variable among distinct
P. vivax populations worldwide. Using the same panel of
17 microsatellites, 100% of P. vivax infections in southern
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Study
region
Study [reference] Year samples
collected
Number of samples
analysed
Marker Proportion infections with
multiple clones (%)
Mean
MOI
Asia
Thailand Imwong et al. 2007
[27]
1992-1993 92 Microsatellites 30 - > 60 1.4
Imwong et al. 2005
[30]
1995-1998 100 CSP + MSP1 26 1.29
MSP3a 19.3
CSP + MSP3a 35.6
Laos Imwong et al 2007
[27]
2001-2003 81 Microsatellites 30 - > 60 1.5
Vietnam Van den Eede et al.
2010 [33]
1999-2000 69 Microsatellites 100 3.7
India Prajapati et al. 2006
[34]
2000-2004 252 GAM-1 13.09 N/S
Imwong et al. 2007
[27]
2003-2004 90 Microsatellites 10-40 1.2
Kim et al. 2006 [35] 2003-2004 151 CSP, MSP1, MSP3a 10.6 N/S
Sri Lanka Wickramara-chchi et al.
2010 [36]
1998-2000 201 MSP3a 13.8-20 N/S
Karunaweera et al.
2008 [26]
2005 50 Microsatellites 9.1-60 N/S
Gunawardena et al.
2010 [37]
2003-2008 140 Microsatellites 55 N/S
MSP3a 6 N/S
Pakistan Khatoon et al. 2010
[38]
[2007] 50 MSP3b 12
MSP3a + MSP3b 2 N/S
Zakeri et al. 2010 [39] 2008 187 CSP, MSP-1, MSP3a 30
China 2004 54: Anhui Province 5.6 N/S
Yang et al. 2006 2005 31: Guizhou Province MSP3b 0
2004 14: Guangxi Province 0
Zhong et al. 2011 [41] 2006-2008 140 MSP3a 7.6-14.3 N/S
MSP3b 14.3-15
Myanmar Kim et al. 2010 [42] 2000 96 CSP 24.5 N/S
CSP 24.1 N/S
Moon et al. 2009 [43] 2004 349 MSP1 16.4
MSP3a 21.6
Zhong et a.l 2011 [41] 2006-2008 72 MSP3a 10.2 N/S
MSP3b 16.4
Gunawardena et al.
2010 [37]
2007 167 Microsatellites 67.1 N/S
East Timor Chen et al. 2007 [44] 2001 17 CSP, MSP-1, AMA-1 35 N/S
Middle East
Iran Zakeri et al. 2003 [45] 2000-2001 107 MSP-1 20 N/S
Zakeri et al. 2006 [46] 2000-2003 374 CSP 12 N/S
Zakeri et al. 2006 [47] 2000-2003 144 MSP3a 3.5 N/S
Zakeri et al. 2010 [39] 2008 150 CSP, MSP-1, MSP3a 24.6 N/S
Uzbekistan Severini et al. 2004
[48]
1999-2002 12 indigenous cases MSP-1 8 N/S
10 imported cases 10
Afghanistan CSP 6.4
Zakeri et al. 2010 [49] 2007 202 MSP-1 0 N/S
MSP3a 3.5
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11-70% polyclonality observed following analysis of iso-
lates collected in the Peruvian Amazon [28] (Table 1).
Similarly, when using a panel of nine microsatellites
Imwong and colleagues reported low genetic diversity,
high levels of inbreeding and linkage disequilibrium in
Colombia, compared to high levels of genetic diversity in
India, Thailand and Laos [27] (Table 1). These results
emphasize that it cannot be assumed that global parasite
populations are equivalent and as a result, may not be
impacted by intervention measures to the same extent.
In order to enable accurate comparisons of genetic
diversity of global P. vivax populations, a standardized
approach to microsatellite genotyping is required, similar
to that implemented for investigation of P. falciparum
[67]. However, there remain a number of challenges and
limitations to developing such an approach. Selection of
both the appropriate number and length of microsatel-
lites to be used for genotyping is crucial to obtain accu-
rate results [29]. Increasing the number of markers
investigated increases the likelihood of detecting multiple
clone infections. Havryliuk and colleagues reported that a
Table 1 Global detection of multiple clone infections using molecular markers in Plasmodium vivax populations
(Continued)
Turkey Zeyrek et al. 2010 [50] 2007-2008 31 MSP-1 3.2 N/S
Africa N/S
Ethiopia Gunawardena et al.
2010 [37]
2006-2008 118 Microsatellites 73.70 N/S
South & Central America
Mexico Joy et al. 2008 [20] 1997-2005 234 Microsatellites 15.8 1.01
Peru Sutton et al. 2009 [51] 2003-2004 186 MSP3a 26.3 2-3
a
Van den Eede et al.
2010 [28]
2006-2008 159 Microsatellites 11-70 1.1
Brazil Ferreira et al. 2007 [2] 1999 74 Microsatellites 48 (1999) N/S
2004-2005 49 (2004-5)
Rezende et al. 2009
[52]
2003-2005 44 Tandem repeats 0-66 N/S
Rezende et al. 2010
[53]
2003-2005 53 Microsatellites 32-57 N/S
Storti- Melo et al. 2009
[54]
2003-2005 155 CSP 0-39.3 N/S
Orjuela-Sanchez et al.
2009 [55]
2005-2007 77 Microsatellites 10.1-42.4 N/S
French
Guiana
MSP-1 (57 samples) 12.3 N/S
Veron et al. 2009 [56] 2005-2006 109 MSP3a (109
samples)
13.8
MSP-1 + MSP3a (57
samples)
21
Guyana Bonilla et al. 2006 [57] 2000 61 CSP 39.3 N/S
Colombia Imwong et al. 2007
[27]
2001-2003 82 Microsatellites 10-40 1.1
Cristiano et al. 2008
[58]
2006 55 MSP3a 36.4 N/S
Venezuela Ord et al. 2005 [59] 1995-1997 58 MSP3a 10 N/S
Leclerc et al. 2005 [60] Not stated 39 MSP-1 0 N/A
Oceania
Papua New
Guinea
Henry-Halldin et al.
2011 [61]
2001-2003 703: Wosera region CSP 36.8 N/S
986: Mugil region 34.4
Mueller et al. 2002 [62] 2002 11 MSP3a 18 N/S
Koepfli et al. 2009 [63] 2004-2005 108 Microsatellites 81.4 1-8
Gomez et al. 2003 [64] Not stated 89 pvMS1 4.5 N/S
aMean MOI was not reported, shown is the observed COI range
N/S: Mean MOI was not reported; N/A: none of the samples tested were polyclonal
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90% of multiple clone infections amongst samples col-
lected in Acre, Brazil and that 11 markers enabled 100%
of multiple clone infections to be identified [25]. In addi-
tion, it is known that repeat length can influence diversity
associated with a microsatellite, with longer arrays of di-,
tri- and tetra-nucleotide repeats more diverse than
shorter sequences [2,53,68-71].
The diversity of a given microsatellite, and the number
of microsatellites required to accurately genotype P.
vivax strains will differ in different epidemiological set-
tings and geographic regions [27,33,63]. Gunawardena
and colleagues reported diversity of the MS16 microsa-
tellite was far higher amongst Sri Lankan P. vivax
strains compared to strains collected in Ethiopia, despite
a higher rate of polyclonal infections detected amongst
the Ethiopian samples tested [37] (Table 1). A similarly
high level of MS16 diversity was observed by Koepfli
and colleagues, reporting that more clones were
detected using MS16, compared with the MSP1-f3 mar-
ker amongst strains from Papua New Guinea (PNG),
due to a greater likelihood of clones sharing the same
MSP1-f3 allele [72]. Furthermore, the same authors also
demonstrated that in the context of a multiple clone
infection, clones representing a minority of the popula-
tion may be missed by PCR, and that detectability of
specific P. vivax clones in a particular individual varied
depending on the day that sample was collected [72].
Taken together, these results suggest that prior to devel-
opment of a standardized strategy for P. vivax genotyp-
ing, the suitability of candidate markers must be widely
assessed in distinct populations. In addition to identify-
ing suitable markers, the criteria for assigning minor/
multiple alleles must also be standardized to further
limit discrepancies reported between studies.
The importance of Plasmodium vivax population
genetics studies
Identifying routes of transmission and gene flow
Investigating the genetic diversity of Plasmodium vivax
populations is essential from both a public health per-
spective, and
to help achieve malaria control and elimination.
Detection and analysis of individual clones within popu-
lations has not only provided a greater understanding of
genetic diversity, but also of P. vivax prevalence and
incidence [31,46,73,74]. Prevalence is one indicator of
transmission and the main malariometric measurement
in investigations including the global Malaria Atlas Pro-
ject (MAP) [75]. For control and elimination strategies
to succeed, the origin and movement of P. vivax popula-
tions must be identified, which can be achieved by geno-
typing isolates from several different regions. Using a
panel of 12 microsatellite markers, Gunawardena and
colleagues reported that isolates collected in Sri Lanka,
Myanmar and Ethiopia all clustered according to their
geographic origins, demonstrating that these microsatel-
lites may be used to map the origin of P. vivax isolates,
at least on a broad continental scale [37]. Genome-wide
single nucleotide polymorphisms (SNPs) may provide a
higher resolution for geographic positioning on a local
scale, however such SNPs have not yet been identified
for P. vivax.
The construction of population structure networks
and maps demonstrating genetic relatedness of parasites
in specific regions can enable not only the identification
of parasite origins but also routes of population move-
ment, and therefore the likelihood of successful elimina-
tion within a given region with respect to parasite
diversity, population movement and the burden of
imported cases [76]. The Pacific Malaria Initiative
(PacMI) recently reported the results of an epidemiolo-
gical survey performed in order to investigate the likeli-
hood of success of potential malaria elimination
campaigns in two isolated island provinces of Vanuatu
and the Solomon Islands, Tafea and Temotu provinces,
respectively [77]. The results of prior studies conducted
in other provinces of both nations reported a predomi-
nance of P. falciparum, with high parasite prevalence
(up to 35%) and transmission rates [77-80]. Although
extensive genetic characterization of the parasite popula-
tions was not performed, the results of the recent PacMI
survey revealed that compared to other provinces within
each country, the malaria epidemiology in the isolated
Tafea and Temotu provinces was hypoendemic, with
low parasite prevalence and a predominance of P. vivax
[77]. Coupled with restricted travel and screening of
incoming passengers for infection with malaria parasites,
both island provinces were flagged as candidates for
future malaria elimination campaigns [77].
Porous land borders between malaria endemic coun-
tries, specifically throughout Southeast Asia and the
Middle East, are potential barriers to the successful
implementation of malaria elimination campaigns
[77,81]. Migration of infected individuals resulting in
importation of Plasmodium spp. and subsequent trans-
mission by local vectors has contributed to the global
spread of malaria [82]. Migration of infected individuals
may seriously confound containment of P. vivax,a s
individuals can be unaware of their infection status due
to long incubation periods. Hence, the potential for
reintroduction of endemic malaria into non-endemic
countries, is high. Khan and colleagues recently reported
both detection of competent malaria vectors and an
increase in malaria cases, mostly due to P. vivax,i n
Qatar, due to a massive influx of migrant workers from
India and Pakistan [83]. Imported cases also have the
potential to increase genetic diversity of existing P.
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Following reports of increasing P. vivax genetic diversity
in Korea [84], Choi and colleagues used genotyping to
successfully distinguish between autochthonous and
imported P. vivax cases, identifying that the imported
infections originated in neighbouring Asian countries.
Imported infections also pose a risk in non-endemic
regions of endemic countries. Many South American
countries are geographically heterogeneous with regard
to malaria transmission, and imported cases can result
in serious illness and death amongst non-immune popu-
lations [85].
Genotyping imported infections is also essential to
monitor the introduction and spread of drug resistance
into sensitive populations. Population genetic surveys in
Venezuela enabled identification of the introduction and
spread of chloroquine resistant P. falciparum,r e s u l t i n g
in changes to the national malaria treatment guidelines
and rollout of more effective anti-malarials to combat
the spread of drug resistance [82].
Combined, the results of these studies demonstrate
the importance of population surveillance; to enable
identification of routes of P. vivax introduction to, and
transmission within, a given population. To achieve
malaria elimination targets, the movement of P. vivax
populations must be controlled to limit not only reintro-
duction of the disease into non-endemic countries, but
also to restrict global genetic diversity and the spread of
drug resistance.
Impact assessment of intervention and vector
control strategies
Investigation of genetic diversity within P. vivax popula-
tions is a useful gauge of both the likelihood of success
and subsequently, the impact of intervention methods.
Interventions such as anti-malarials and candidate vac-
cines would be anticipated to be more successful in a
population with low genetic diversity and any reduction
in genetic diversity following the introduction of inter-
vention measures may be regarded as an indicator of
success.
In the absence of a continuous in vitro culture system
and defined markers to identify drug resistance, geno-
typing is currently used to monitor treatment efficacy,
and the emergence of resistant P. vivax strains. An
understanding of haplotype frequency within a given
population is therefore essential [86]. With respect to P.
vivax parasites detected following drug treatment, there
are three possible sources: re-infection with a new
clone, recrudescence of a drug resistant clone, or relapse
as a result of reactivation of liver hypnozoites [87]. As
biomarkers do not currently exist to determine whether
recurrent P. vivax parasitaemia is due to reactivation of
liver hypnozoites, genotyping is used to identify whether
recurrent episodes of P. vivax infection are the result of
re-infection with a new clone or recrudescence/relapse
of an existing drug-resistant clone [87,88]. The basis for
this approach is that genetic diversity is sufficient to be
able to distinguish between strains using a panel of
diverse markers [86]. Confounding the distinction
between relapse and re-infection, Imwong and collea-
gues reported that contrary to the long-held belief that
reactivated hypnozoites were genetically identical to the
strain responsible for primary infection, reactivated hyp-
nozoites might indeed be heterologous [87]. Hence, it
may not always be possible to distinguish re-infection
from relapse, especially in regions with reduced parasite
diversity. To maximize the ability to distinguish between
strains, a panel of diverse markers should be used
[63,86,89]. The markers used must be sufficiently
diverse and located in distinct genomic positions, how-
ever markers may be more or less suited for use depen-
dent upon genetic diversity within a given population
[27,63,86]. As a result, community-based investigations
of parasite diversity and allele frequencies are vital to
enable accurate analysis of anti-malarial interventions
[27,86].
The impact of vector control strategies, such as insec-
ticide spraying, is also measurable using population
genetics methods. Jongwutiwes and colleagues reported
differences in the diversity of P. vivax amongst popula-
tions in the north-west and south of Thailand [90]. Lim-
ited diversity, suggestive of a recent population
bottleneck was observed in the south, where anti-malar-
ial insecticide spraying had been implemented and was
ongoing. In the north-west, a region bordering Myan-
mar, anti-malarial control measures have not been
implemented to the same extent as in the south, and as
a result, diversity of the P. vivax population investigated
was high [90].
Identification of immunogenic targets and
potential vaccine candidates
Development of a vaccine targeting P. vivax lags far
behind efforts to design a vaccine against P. falciparum
[ 9 1 ] .T h i si sa ni n e v i t a b l er e f l e c t i o no ft h er e d u c e d
research focus on P. vivax. The main obstacle impeding
P. vivax research is the lack of available parasite mate-
rial, since P. vivax cannot be continuously cultured in
vitro and infected individuals typically present with low
parasitaemia [92-95]. As a result, the majority of clinical
immunology studies rely on using recombinant P. vivax
proteins, typically expressed from reference strains [95].
However, an understanding of population genetic struc-
ture can also give insight into the development of host
immune responses. Population genetics studies can
identify signatures of balancing selection within parasite
surface antigen genes, enabling identification of domains
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tification of potential vaccine candidates, as has been
done for P. falciparum [23,96,97]. The utility of diversity
data is enhanced when additional information is known,
such as the allelic frequency wi t h i nag i v e np o p u l a t i o n
[96]. For example, in a population with low microsatel-
lite diversity, low diversity amongst genes encoding anti-
gens would also be expected. As strain-specific
immunity is thought to be a major reason for the failure
of malaria vaccine trials to date [98], reduced diversity
amongst antigen-encoding genes would encode less
diverse surface antigens, increasing the breadth of vac-
cine efficacy, and the generation of effective immune
responses [99,100].
T h e r ea r et h r e ep h a s e so ft h em a l a r i ap a r a s i t el i f e -
cycle that could be effectively targeted by host immune
responses: inhibition of hepatocyte invasion at the pre-
erythrocytic stage (e.g. vaccines targeting antigens such
as CSP), inhibition of erythrocyte invasion during the
asexual blood stage (merozoite surface protein 1,
MSP1; apical membrane antigen 1, AMA1), and inhibi-
tion of parasite fertilization and development in the
mosquito midgut (oocyst/ookinete 25 kD surface pro-
tein, Pvs25) [91,101]. The majority of the vaccine can-
didates currently under investigation for P. vivax are
orthologues of P. falciparum vaccine candidate anti-
gens [91,101]. However, due to biological differences,
and differences in the extent and distribution of
genetic diversity, it is not always possible to draw con-
clusions for P. vivax on the basis of what is known for
P. falciparum. Few studies have been performed to
investigate the diversity of vaccine candidate antigens
in sympatric populations. This is despite the fact that
many believe a globally effective malaria vaccine must
contain not only multiple antigens, but also a combi-
nation of P. falciparum and P. vivax antigens due to
sympatric circulation of both species in many endemic
regions [101]. Indeed, differences may exist between
regions of the same antigen under immune pressure in
P. falciparum and P. vivax parasites, as has been
reported for AMA1 [97,102-104]. Assessment of
genetic diversity, and therefore suitability of candidate
antigens is therefore essential to design an effective
multi-species and/or a P. vivax vaccine.
Conclusions
Partly as a consequence of the common misconception
that P. vivax infection is benign, research funding and
focus directed towards this neglected malaria parasite
has been limited relative to P. falciparum.A sar e s u l t ,
much remains unknown regarding P. vivax biology, epi-
demiology and pathogenesis. However, it is now under-
stood that globally, P. vivax populations are highly
genetically diverse, and that this diversity varies greatly
according to geographic region. In order to achieve
malaria control and elimination targets, population
genetic surveys are vital to map the diversity and struc-
ture of local populations and to estimate the likelihood
of success and measure the outcome of malaria inter-
vention methods. To assist vaccine development, genetic
structure and diversity of candidate antigens needs to be
assessed in sympatric P. vivax and P. falciparum popula-
tions worldwide.
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